Evidence map›Paper›PMID 42051293›Full record

ArticlebioRxiv : the preprint server for biology2026

Multiple Sclerosis Drug Fingolimod Exhibits Antibacterial Activity through Bacterial Membrane Permeabilization.

Antara Syam, Benjamin Rees, Sebastian Cuervo, Fengtian Xue, Alexander Sodt, Ekaterina M Nestorovich, Tatiana K Rostovtseva, Sergey M Bezrukov, John S Choy

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antara SyamDepartment of Biology, The Catholic University of America, Washington, DC, 20064, USA.
Benjamin ReesDepartment of Biology, The Catholic University of America, Washington, DC, 20064, USA.
Sebastian CuervoDepartment of Biology, The Catholic University of America, Washington, DC, 20064, USA.
Fengtian XueDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.
Alexander SodtEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA.ORCID 0000-0002-5570-8212
Ekaterina M NestorovichDepartment of Biology, The Catholic University of America, Washington, DC, 20064, USA.
Tatiana K RostovtsevaEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA.
Sergey M BezrukovEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA.
John S ChoyDepartment of Biology, The Catholic University of America, Washington, DC, 20064, USA.ORCID 0000-0001-9196-3280

Funding

Biophysics of Large Membrane ChannelsZIAHD000072 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI BEZRUKOV, SERGEY M · 2009 to 2025
$22.8M
Characterizing Regulatory Mechanisms Underlying Drug Resistance in Breast Cancer Using Keratin 19R15CA267890 · NCI · CATHOLIC UNIVERSITY OF AMERICA · PI CHOY, JOHN SING · 2022 to 2022
$473k
Intramural NIH HHS ZIA HD000072NCI NIH HHS R15 CA267890
6 · The paper itself

Abstract

Although receptor-mediated mechanisms account for the therapeutic action of numerous FDA-approved drugs, emerging evidence suggests that many of these therapeutics have off-target antimicrobial activities. One example is fingolimod, an immunomodulator used to treat multiple sclerosis, that has been reported to have antimicrobial effects associated with membrane permeabilization. Yet the molecular mechanism by which fingolimod alters bacterial membranes remains unknown. As a cationic amphiphilic drug (CAD), fingolimod is comprised of both hydrophobic and positively charged regions that can enable membrane interactions. We show that fingolimod compromises membrane integrity in

Indexed as

antimicrobial effectCationic Amphiphilic DrugsGramicidin A channelmicrobiological assayMolecular dynamics simulationMultiple SclerosisPlanar lipid membrane

Identifiers

PMID42051293
PMCPMC13119335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.